A Phase 4 interventional study of Ningmitai capsule and Celecoxib capsule in Chronic Prostatitis, sponsored by Xintian Pharmaceutical. Completed at 1 site in China. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Xintian Pharmaceutical · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Prostatitis with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Prostatitis · China.
Among the 13 studies in Prostatitis with a site in China, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 4, and was the 11th registered.
89 studies on the registry are indexed under Prostatitis; 12 are open to participants now.
Browse Prostatitis studies →2 of the 13 studies in Prostatitis with a site in China are open now. Recruiting first, the newest first:
Jiani Wu · Sites in China
Ages 18–50 · Men only
Shaanxi Provincial People's Hospital · Sites in China
Ages 18+ · Men only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 6 Prostatitis studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 60 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 242 is above the median of 61 across 74 interventional studies indexed under Prostatitis.
Median enrollment 211 across the 12 interventional studies, 400 across the 1 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 8 most frequent:
Xintian Pharmaceutical is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Xintian Pharmaceutical has 3 studies filed under Prostatitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Prostatitis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06287970Jiani WuTaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Prostatitis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Clinical trial title:Efficacy and safety of Ningmitai capsule alone or combined with celecoxib in the treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): A prospective, randomized, double-blind, multicenter clinical study Principal investigator:Zhou Huiliang Main research units:The First Affiliated Hospital of Fujian Medical University Clinical trial start and end dates:2023/07/01-2025/12/31 Objective: To evaluate whether Ningmitai capsule(NMT) alone or combined with Celecoxib for 6 weeks is more effective than Celecoxib in improving pain symptoms of CP/CPPS patients.
Study type: Interventional study Total sample size:240
Inclusion criteria:
Exclusion criteria:
Interventions:
Clinical trial title:Efficacy and safety of Ningmitai capsule alone or combined with celecoxib in the treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): A prospective, randomized, double-blind, multicenter clinical study Principal investigator:Zhou Huiliang Main research units:The First Affiliated Hospital of Fujian Medical University Clinical trial start and end dates:2023/07/01-2025/12/31 Objective: To evaluate whether using Ningmitai capsule(NMT) alone or combined with Celecoxib for 6 weeks is more effective than Celecoxib in improving symptoms especially pain of CP/CPPS patients.
Study type: Interventional study Total sample size: 240
Inclusion criteria:
Exclusion criteria:
Interventions:
Ningmitai group Orally administered Ningmitai capsule and Celecoxib placebo after meals for 6 weeks.
Ningmitai capsule: 0.38 g/capsule, tid, 4 capsules each time; Celecoxib placebo: 0.2 g/capsule, qd,1 capsule each time. Sample size: 80
Celecoxib group Orally administered Celecoxib capsule and Ningmitai placebo after meals for 6 weeks.
Celecoxib capsule: 0.2 g/capsule, qd,1 capsule each time; Ningmitai placebo: 0.38 g/capsule, tid, 4 capsules each time. Sample size: 80
Ningmitai capsule: 0.38 g/capsule, tid, 4 capsules each time; Celecoxib capsule: 0.2 g/capsule, qd,1 capsule each time. Sample size: 80 Treatment cycle:6 weeks. the trial treatment began on the day of randomization. Visiting nodes:① before treatment (-2 weeks to 0 days), ②2 weeks of treatment (14 ± 2 days), ③ 4 weeks of treatment (28 ± 5 days).④ 6 weeks of treatment(42 ± 7 days). ⑤week 8 (2 weeks after treatment cessation, 56 ± 7 days).
Countries of recruitment and research settings:
Country:China Province:Fujian Institutions (hospitals): The First Affiliated Hospital of Fujian Medical University, The First Affiliated Hospital of Xiamen University.
Recruiting status: Not yet recruiting Randomization Procedure:In this study, the research center was used as the stratification factor of random assignment. Subjects were randomly assigned (1:1:1) to NMT group, Celecoxib group and combination group according to the random allocation table (subject random code) simulated by SAS 9.2 software. Subjects' random numbers cannot be reused by other subjects, whether they are using the study drug or not, or the study is terminated for any reason.
Sign the informed consent: Yes. Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:In this study, case report form (CRF) was used to collect and manage research data. The sponsor or designated person is responsible for data management of the study, including data quality control. The workflow of data management includes data entry, data verification and query, medical coding, data audit, database locking, data export and transmission, data and data management file archiving, etc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules and celexcoib placebo, 0.2 g/ capsule, 1 capsule, qd each time, after meals, for 6 weeks.
Drug: Ningmitai capsule · Drug: Celecoxib placebo
Patients take celexcoib capsule, 0.2 g/capsule, qd, 1 capsule and Ningmitai placebo, 0.38 g/ capsule, 4 cpsule, tid each time, after meals, for 6 weeks.
Drug: Celecoxib capsule · Drug: Ningmitai placebo
Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules and celexcoib capsule, 0.2 g/ capsule, 1 capsule, qd each time, after meals, for 6 weeks.
Drug: Ningmitai capsule · Drug: Celecoxib capsule
Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.
Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.
Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
Pain score of the National Institutes of Health Chronic Prostatitis Symptom Index
The change of NIH-CPSI pain score from baseline to 6 weeks. National Institutions of Health Chronic Prostatitis Symptom Index(NIH-CPSI,0\~43 points) consists of three subscales. The first part is pain symptoms, which consists of questions 1\~4 (0\~21 points), and evaluates the location, frequency and severity of pain. The second part is urination symptoms, which consists of questions 5\~6 (0 \~ 10 points), and evaluates the severity of incomplete urination and frequent urination; The third part is to evaluate the impact on the quality of life, which consists of questions 7\~9 (0\~12 points).The higher the score, the more serious the symptoms of chronic prostatitis.
Time frame: Treatment for 6 weeks
Pain score of the National Institutes of Health Chronic Prostatitis Symptom Index
The change of NIH-CPSI pain score from baseline to 2, 4, 8 weeks,respectively. National Institutions of Health Chronic Prostatitis Symptom Index(NIH-CPSI,0\~43 points) consists of three subscales. The first part is pain symptoms, which consists of questions 1\~4 (0\~21 points), and evaluates the location, frequency and severity of pain. The second part is urination symptoms, which consists of questions 5\~6 (0 \~ 10 points), and evaluates the severity of incomplete urination and frequent urination; The third part is to evaluate the impact on the quality of life, which consists of questions 7\~9 (0\~12 points).The higher the score, the more serious the symptoms of chronic prostatitis.
Time frame: Week 2, 4, 8
Total score, urinary score and quality of life score of the National Institutes of Health Chronic Prostatitis Symptom Index
The change of NIH-CPSI total score, urinary score and quality of life score from baseline to 2, 4, 6, 8 weeks. National Institutions of Health Chronic Prostatitis Symptom Index(NIH-CPSI,0\~43 points) consists of three subscales. The first part is pain symptoms, which consists of questions 1\~4 (0\~21 points), and evaluates the location, frequency and severity of pain. The second part is urination symptoms, which consists of questions 5\~6 (0 \~ 10 points), and evaluates the severity of incomplete urination and frequent urination; The third part is to evaluate the impact on the quality of life, which consists of questions 7\~9 (0\~12 points).The higher the score, the more serious the symptoms of chronic prostatitis.
Time frame: Week 2, 4, 6, 8
The scores of questions 1~4 of the National Institutes of Health Chronic Prostatitis Symptom Index
The change of scores of NIH-CPSI questions 1\~4 from baseline to 2 weeks. Questions 1\~4 (0\~21 points) evaluates the location, frequency and severity of pain. The higher the score, the more serious the pain symptoms of chronic prostatitis.
Time frame: Treatment for 2 weeks
The scores of questions 1~4 of the National Institutes of Health Chronic Prostatitis Symptom Index
The change of scores of NIH-CPSI questions 1\~4 from baseline to 4 weeks. Questions 1\~4 (0\~21 points) evaluates the location, frequency and severity of pain. The higher the score, the more serious the pain symptoms of chronic prostatitis.
Time frame: Treatment for 4 weeks
The scores of questions 1~4 in the National Institutes of Health Chronic Prostatitis Symptom Index
The change of scores of questions 1\~4 in NIH-CPSI from baseline to 6 weeks. Questions 1\~4 (0\~21 points) evaluates the location, frequency and severity of pain. The higher the score, the more serious the pain symptoms of chronic prostatitis.
Time frame: Treatment for 6 weeks
Response rate
The response rate is defined as a decrease of at least 2 points in the NIH-CPSI pain score and at least 4 points in the NIH-CPSI total score, respectively.
Time frame: Treatment for 2 weeks, 4 weeks and 6 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Jan 2025, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Xintian Pharmaceutical